Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma.
IGF-binding protein
drug resistance
glioblastoma
insulin-like growth factor signaling pathway
insulin/insulin-like growth factor system
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
09
2020
accepted:
16
12
2020
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) is the most common primary brain malignancy and is often resistant to conventional treatments due to its extensive cellular heterogeneity. Thus, the overall survival of GBM patients remains extremely poor. Insulin-like growth factor (IGF) signaling entails a complex system that is a key regulator of cell transformation, growth and cell-cycle progression. Hence, its deregulation is frequently involved in the development of several cancers, including brain malignancies. In GBM, differential expression of several IGF system components and alterations of this signaling axis are linked to significantly worse prognosis and reduced responsiveness to temozolomide, the most commonly used pharmacological agent for the treatment of the disease. In the present review we summarize the biological role of the IGF system in the pathogenesis of GBM and comprehensively discuss its clinical significance and contribution to the development of resistance to standard chemotherapy and experimental treatments.
Identifiants
pubmed: 33604294
doi: 10.3389/fonc.2020.612385
pmc: PMC7885861
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
612385Informations de copyright
Copyright © 2021 Tirrò, Massimino, Romano, Martorana, Pennisi, Stella, Pavone, Di Gregorio, Puma, Tomarchio, Vitale, Manzella and Vigneri.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neuro Oncol. 2016 Jan;18(1):48-57
pubmed: 26136493
J Mol Endocrinol. 2018 Jul;61(1):T69-T86
pubmed: 29535161
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Endocr Relat Cancer. 2001 Sep;8(3):197-209
pubmed: 11566611
J Neurosurg. 2014 Aug;121(2):374-83
pubmed: 24878287
Arch Pharm Res. 2020 Apr;43(4):385-394
pubmed: 32239429
Neuroscience. 2007 Mar 30;145(3):795-811
pubmed: 17320297
PLoS One. 2019 Dec 5;14(12):e0225913
pubmed: 31805126
Ann Oncol. 2017 Jul 1;28(7):1448-1456
pubmed: 28407030
Endocr Relat Cancer. 2019 Jan 1;26(1):197-214
pubmed: 30121624
Cancer Res. 2002 Jan 1;62(1):200-7
pubmed: 11782378
Oncol Rep. 2014 Mar;31(3):1445-52
pubmed: 24378652
J Neurooncol. 2014 Feb;116(3):455-64
pubmed: 24395346
Science. 2016 May 20;352(6288):aad3018
pubmed: 27199435
PLoS One. 2016 Nov 28;11(11):e0167096
pubmed: 27893811
Target Oncol. 2017 Oct;12(5):571-597
pubmed: 28815409
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
Front Endocrinol (Lausanne). 2015 May 15;6:77
pubmed: 26029167
Nat Rev Dis Primers. 2015 Jul 16;1:15017
pubmed: 27188790
Exp Ther Med. 2018 Aug;16(2):1477-1482
pubmed: 30116397
J Biol Chem. 2014 Sep 5;289(36):25079-87
pubmed: 25059666
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Anticancer Res. 2008 Mar-Apr;28(2A):1055-60
pubmed: 18507054
Anticancer Res. 2019 Jul;39(7):3893-3899
pubmed: 31262918
Clin J Oncol Nurs. 2011 Jun;15(3):291-7
pubmed: 21624864
Oncotarget. 2017 Jun 27;8(26):43248-43270
pubmed: 28591735
Proteomics. 2006 May;6(10):2964-71
pubmed: 16619307
Med Oncol. 2013;30(2):557
pubmed: 23564324
Oncol Res. 2017 Jan 26;25(2):187-194
pubmed: 28277190
Stem Cells. 2013 Apr;31(4):627-40
pubmed: 23335250
Cell Div. 2020 Feb 27;15:4
pubmed: 32127912
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
J Neuropathol Exp Neurol. 2007 May;66(5):405-17
pubmed: 17483698
Cochrane Database Syst Rev. 2020 May 12;5:CD013238
pubmed: 32395825
Front Oncol. 2019 Feb 18;9:57
pubmed: 30834235
Signal Transduct Target Ther. 2017 Sep 29;2:17040
pubmed: 29263927
EBioMedicine. 2020 May;55:102736
pubmed: 32361246
Crit Rev Oncog. 2019;24(3):243-250
pubmed: 32422022
Oncogene. 2016 Feb 11;35(6):738-47
pubmed: 25893308
Br J Cancer. 2020 Mar;122(5):624-629
pubmed: 31857716
Mol Med Rep. 2015 Oct;12(4):5641-6
pubmed: 26238593
Mol Med Rep. 2017 Nov;16(5):7821-7828
pubmed: 28944896
Mol Cancer Ther. 2017 Apr;16(4):705-716
pubmed: 28138037
Glia. 2006 Jun;53(8):845-57
pubmed: 16586492
Diagn Pathol. 2014 Nov 14;9:211
pubmed: 25394492
Cell Mol Neurobiol. 2017 Jul;37(5):889-898
pubmed: 27650075
Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3475-80
pubmed: 22345562
Clin Cancer Res. 2015 Apr 1;21(7):1558-65
pubmed: 25467181
Nat Med. 2013 Oct;19(10):1264-72
pubmed: 24056773
Front Oncol. 2015 Jul 15;5:157
pubmed: 26236690
J Clin Oncol. 2001 Apr 15;19(8):2189-200
pubmed: 11304771
Genes (Basel). 2019 Sep 13;10(9):
pubmed: 31540307
Curr Pharm Des. 2014;20(17):2912-21
pubmed: 23944361
Drug Resist Updat. 2019 Mar;43:29-37
pubmed: 31054489
Eur Rev Med Pharmacol Sci. 2015;19(9):1630-9
pubmed: 26004603
JAMA Oncol. 2018 Sep 1;4(9):1254-1262
pubmed: 29931168
Anticancer Res. 2018 Dec;38(12):6653-6662
pubmed: 30504373
Cancer Res. 2000 Dec 1;60(23):6617-22
pubmed: 11118044
Oncogene. 2015 Mar 26;34(13):1619-1628
pubmed: 24747968
Exp Ther Med. 2019 Apr;17(4):2921-2930
pubmed: 30906475
Jpn J Clin Oncol. 2012 Mar;42(3):196-201
pubmed: 22217575
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1399-408
pubmed: 20501753
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Cancer Res. 2003 Aug 1;63(15):4315-21
pubmed: 12907597
Trends Endocrinol Metab. 2003 May-Jun;14(4):176-81
pubmed: 12714278
Front Oncol. 2015 Oct 15;5:230
pubmed: 26528439
Neuro Oncol. 2009 Oct;11(5):468-76
pubmed: 19164435
Med Sci Monit. 2015 Dec 13;21:3880-6
pubmed: 26656446
Int J Oncol. 2010 Jul;37(1):143-53
pubmed: 20514406
Expert Rev Neurother. 2009 Apr;9(4):519-34
pubmed: 19344303
Neuro Oncol. 2015 Aug;17(8):1076-85
pubmed: 25543125
Neuro Oncol. 2010 Jan;12(1):19-27
pubmed: 20150364
Int J Clin Exp Pathol. 2018 Sep 01;11(9):4405-4413
pubmed: 31949837
Cancer Res. 2008 May 15;68(10):3566-72
pubmed: 18483236
Front Oncol. 2020 May 15;10:727
pubmed: 32500027
J Pharm Pharmacol. 2020 Apr;72(4):531-538
pubmed: 32026479
Int J Cancer. 2011 Nov 15;129(10):2527-31
pubmed: 21213215
J Chemother. 2016;28(1):44-9
pubmed: 25971682
J Biol Chem. 2011 Jul 22;286(29):25882-90
pubmed: 21613208
Tumour Biol. 2014 Nov;35(11):11269-75
pubmed: 25117070
Int J Oncol. 2010 Sep;37(3):633-43
pubmed: 20664932
Cancer Res. 2007 Jan 1;67(1):391-7
pubmed: 17210722
J Neurosurg. 2019 Jan 11;132(1):168-179
pubmed: 30641835
J Cell Physiol. 2011 Apr;226(4):1118-27
pubmed: 20857406
Folia Neuropathol. 2020;58(1):38-44
pubmed: 32337956
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
J Clin Invest. 2017 Feb 1;127(2):415-426
pubmed: 28145904
Genes Dis. 2015 Mar 1;2(1):13-25
pubmed: 25984556
Sci Rep. 2020 May 20;10(1):8348
pubmed: 32433555
Horm Cancer. 2017 Feb;8(1):49-57
pubmed: 27896672
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Clin Cancer Res. 2016 Apr 1;22(7):1767-76
pubmed: 26561558
RNA. 2013 Apr;19(4):552-60
pubmed: 23431408
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3466-71
pubmed: 17360667
Mol Pathol. 2001 Aug;54(4):230-9
pubmed: 11477137
Neuro Oncol. 1999 Apr;1(2):109-19
pubmed: 11550306
PLoS One. 2013 Nov 28;8(11):e81514
pubmed: 24312311
Cell Commun Signal. 2018 Sep 19;16(1):61
pubmed: 30231881
PLoS One. 2017 Mar 21;12(3):e0173890
pubmed: 28323865
Neuropharmacology. 2016 Nov;110(Pt A):362-375
pubmed: 27487563
J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89
pubmed: 10995803
Mol Cancer Ther. 2010 Oct;9(10):2652-64
pubmed: 20924128
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
pubmed: 24137015
Cancer Med. 2017 Feb;6(2):452-462
pubmed: 28064447
Int J Genomics. 2017;2017:7639084
pubmed: 29234674
Curr Protein Pept Sci. 2013 Mar;14(2):133-40
pubmed: 23544423
Neuro Oncol. 2010 Sep;12(9):967-75
pubmed: 20378689
Front Endocrinol (Lausanne). 2018 Apr 09;9:117
pubmed: 29686648
Br J Cancer. 2015 Sep 1;113(5):729-37
pubmed: 26291053
Anticancer Res. 2007 Nov-Dec;27(6A):3685-92
pubmed: 17970029
Int J Mol Sci. 2019 Jul 02;20(13):
pubmed: 31269742